IDENTIFICATION OF RARE DISEASES, AND DEVELOPMENT FIRMS
Executive Summary
IDENTIFICATION OF RARE DISEASES, AND DEVELOPMENT FIRMS can be aided by pharmacists, maintained American Pharmaceutical Association (APhA) Scientific Affairs Director Arthur Horowitz, PhD, at a Dec. 2 meeting of HHS' Orphan Products Board. APhA proposes "greater individual and group participation in the identification of those rare diseases requiring new drug development" and in "solicitation of sponsor commitments," Horowitz said. Pharmacists, pharmaceutical scientists, and pharmacy students represent "an important resource not fully utilized by the Orphan Products Board," Horowitz contended. "It is generally the pharmacist who has the most frequent contact with patients with rare diseases and who can counsel the patient regarding therapies. The network of many pharmaceutical scientists can identify additional sponsor commitments or provide specific expertise in the manufacture of a certain type of product." APhA also urged greater efforts to publicize the availability of orphan products to patients and to health care providers. The board should "work with all health care providers associations to guarantee continued publicity for newly approved orphan drugs," Horowitz said. For example, HHS should take advantage of "the over 150,000 pharmacists to inform the general public" about the National Information Center for Orphan Drugs and Rare Diseases and its toll-free telephone hotline. The department should also "develop consumer-oriented spot television and radio advertisements to inform the public on the availability of new orphan drugs," he continued. In addition, lists of FDA-approved orphan drugs and products being developed should be published in the FDA Bulletin and the FDA Electronic Bulletin Board.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth